Tangeretin and weight loss before competition: a small trial in female combat sport athletes

A supplement tested during simulated preparation

The study involved women practicing wrestling, boxing, sanda, judo and taekwondo. Participants were matched by sport and competition level, then randomly assigned to two groups of 15 people. The trial was double-blind and included a placebo group.

The experimental group received 400 mg of tangeretin per day for 30 days. This is the dose studied, not a recommendation for use. The researchers assessed body composition, several blood parameters, muscle strength and aerobic capacity in a simulated pre-competition weight-loss setting.

Observed changes, without a quantifiable comparative advantage

In the tangeretin group, 80% of participants lost weight and five reached the weight corresponding to their competition category. However, the abstract specifies neither the average amount of weight lost nor the corresponding results in the placebo group. These proportions therefore do not establish the supplement’s specific efficacy.

Average body fat percentage fell from 23.92% to 22.92%, a decrease of one percentage point. Reductions in fat in several body regions were also reported. Here again, numerical differences compared with placebo are not presented in the excerpt.

Aerobic capacity measured by VO₂max increased from 42.80 to 43.46 ml/kg/min in the tangeretin group. The abstract also reports increased strength during lower-limb joint tests. These measurements alone do not demonstrate better performance in combat or actual competition.

An exploratory signal, not a validated strategy

Random allocation, the placebo control and double blinding strengthen the value of this trial. However, the sample remains small, follow-up is short and numerous outcomes were assessed. The abstract does not allow readers to verify how multiple comparisons were accounted for or to precisely assess the uncertainty surrounding the effects.

The proposed explanations involving hormones and metabolism remain biological hypotheses, not a demonstration of the mechanism responsible for the results. The abstract also provides no summary of adverse effects. The absence of this information does not mean that supplementation is risk-free.

What we can take away

This trial provides a preliminary signal in female combat sport athletes. Without detailed comparative results or safety data available in the abstract, it is not sufficient to recommend tangeretin for reaching a weight category.